IMI Ups the Ante for Diabetes Research

We were recently at the 49th conference of the European Association for the Study of Diabetes (EASD, who featured in previous LillyPadEU blogs ) in Barcelona. At this event three public-private partnerships announced and signed a Memorandum of Understanding to support further Diabetes research. The collaboration platform brings together pharma companies and research universities across Europe and is called The IMI Diabetes Platform, as it is supported by the EU's Innovative Medicines Initiative (IMI) and EFPIA. Lilly is very pleased to be part of this joint venture, alongside other private and academic partners with expertise in Diabetes research and treatments. The platform infuses 100 million euros and a wealth of knowledge and expertise into a field that, unfortunately, continues to affect many people in Europe and beyond, and thus needs both of those resources.

The estimated number of diabetic patients today, worldwide, is 366 million and by 2030 this figure could even go up to 552 million. The burden the disease poses on patients as well as on broader health care systems across the globe is enormous. Having a collective brainpower of over 300 clinicians and scientists from academia and industry looking into solutions for current and future sufferers is a promising step forward. Lilly has been a committed partner in various IMI projects for years and we look forward to bundling our efforts to continue our search for innovative solutions.

Follow the debate online via #EASD2013 and #diabetesresearch

https://s3.eu-central-1.amazonaws.com/lillypad-eu/WP/wp-content/uploads/Lilly-neuron.png
https://s3.eu-central-1.amazonaws.com/lillypad-eu/WP/wp-content/uploads/WWR-picture.jpg